The leukemia therapeutics market is forecast to grow at a CAGR of 8.44% during the period 2016-2020.
Commenting on the report, an analyst from the research team said: One of the key trends for market growth will be the rise in the development of combination therapies. Combination therapies for the treatment of leukemia were available only in the form of combination chemotherapy drugs.
The some of the approved combinations are chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of CLL; a combination of cytarabine, daunorubicin, and etoposide for the treatment of AML; and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of ALL. Also, it has been observed that vendors are showing more interest in the development of combination therapies to treat various leukemias.
According to the report, application for expanded indication approvals will be a key driver for market growth. There has been an increase in the R&D activities going on for the re-positioning of already marketed drugs for the new indications in the global leukemia therapeutics market. This concept of re-positioning came into practice in the early 1990s and is originate from the possibility of different diseases could be sharing common molecular pathways.
The companies are conducting clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is low risk, high reward strategy, this should increase the scope of treatment and hence, help in the increased market penetration.
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the strengths and weaknesses of the key vendors?
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- Teva Pharmaceuticals
- Altor BioScience
- ARIAD Pharmaceuticals
- Arno Therapeutics
- Astex Pharmaceuticals
- Baxter Healthcare
- Bayer HealthCare
- Bellicum Pharmaceuticals
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by disease type
PART 08: Global CLL therapeutics market
PART 09: Global ALL therapeutics market
PART 10: Global AML therapeutics market
PART 11: Global CML therapeutics market
PART 12: Geographical segmentation
PART 13: Market drivers
PART 14: Impact of drivers
PART 15: Market challenges
PART 16: Impact of drivers and challenges
PART 17: Market trends
PART 18: Vendor landscape
PART 19: Key vendor analysis
PART 20: Appendix
PART 21: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/fm577w/global_leukemia
For more information on this topic, please visit the Oncology Drugs section of the Research and Markets Blog.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-leukemia-therapeutics-market-cagr-growth-of-844-by-2020---trends-technologies--opportunities-report-2016-2020---vendors-astrazeneca-baxter-healthcare-bioge-300339883.html
SOURCE Research and Markets